Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 2/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | MIF | P14174 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | NAAA | Q02083 | 3/20 | 0.36 |
| ▸ | APLNR | P35414 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | ACACB | O00763 | 1/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20780041 | 0.85 | NQO1 (0.40) | ACACB | |
| SCHEMBL24184907 | 0.85 | ACACB (0.41) | ACACB | |
| SCHEMBL14015552 | 0.84 | GRM5 (0.36) | KCNH2CA12CA1CA2CA9 | |
| SCHEMBL11552059 | 0.84 | APLNR (0.41) | MIFL3MBTL1NAAAAPLNRCA12 | |
| SCHEMBL91938 | 0.83 | APP (0.50) | APPKCNH2MIFL3MBTL1NAAA | |
| SCHEMBL20780039 | 0.83 | ACACB (0.38) | APPACACBMCHR1 | |
| SCHEMBL24184662 | 0.83 | ACACB (0.40) | ACACB | |
| SCHEMBL24337408 | 0.83 | FFAR1 (0.47) | APPMIFCA12CA1CA2 | |
| SCHEMBL24184899 | 0.82 | ACACB (0.42) | ACACB | |
| SCHEMBL19057523 | 0.81 | FFAR1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230313043-A1 | OPTICAL COMPONENT | MERCK PATENT GMBH (DE) | 2023-10-05 | — | — | US | disclosed |
| WO-2022008474-A1 | OPTICAL COMPONENT | MERCK PATENT GMBH (DE) | 2022-01-13 | — | — | WO | disclosed |
| US-9567522-B2 | Liquid crystal system and liquid crystal display | MERCK PATENT GMBH (DE) | 2017-02-14 | — | — | US | disclosed |
| US-20130193376-A1 | LIQUID CRYSTAL SYSTEM AND LIQUID CRYSTAL DISPLAY | MERCK PATENT GMBH (DE) | 2013-08-01 | — | — | US | disclosed |
| US-8409469-B2 | Liquid crystal system and liquid crystal display | MERCK PATENT GMBH (DE) | 2013-04-02 | — | — | US | disclosed |
| US-8333906-B2 | Liquid crystal system and liquid crystal display | MERCK PATENT GMBH (DE) | 2012-12-18 | — | — | US | disclosed |
| US-8129002-B2 | Compounds for use in liquid crystal media | MERCK PATENT GMBH (DE) | 2012-03-06 | — | — | US | disclosed |
| US-20120012785-A1 | Liquid Crystal System And Liquid Crystal Display | SCHOTT CECILE (TW) | 2012-01-19 | — | — | US | disclosed |
| US-7914859-B2 | Light modulation media, use in particular for electrooptic displays which are operated at a temperature at which the mesogenic modulation media are in an optically isotropic phase, preferably in a blue phase; reduced operating voltage, reduced temperature dependency of operating voltage, reliability | MERCK PATENT GMBH (DE) | 2011-03-29 | — | — | US | disclosed |
| US-20100258763-A1 | LIQUID CRYSTAL SYSTEM AND LIQUID CRYSTAL DISPLAY | SCHOTT CECILE | 2010-10-14 | — | — | US | disclosed |
| US-7794621-B2 | Liquid crystal system and liquid crystal display | MERCK PATENT GMBH (DE) | 2010-09-14 | — | — | US | disclosed |
| US-20090267025-A1 | LIQUID CRYSTAL SYSTEM AND LIQUID CRYSTAL DISPLAY | MERCK PATENT GMBH (DE) | 2009-10-29 | — | — | US | disclosed |
| US-7531106-B2 | Mesogenic compounds, medium for electro-optical displays and electro-optical display | MERCK PATENT GMBH (DE) | 2009-05-12 | — | — | US | disclosed |
| US-20080167482-A1 | mesogenic group is linked to the C-atom No. 5 of the 1,3-dioxane-5-yl group; media showing a blue phase and their use in electro-optical light modulation elements | MERCK PATENT GMBH (DE) | 2008-07-10 | — | — | US | disclosed |
| US-20080116419-A1 | Mesogenic Compounds, Liquid Crystal Medium and Liquid Crystal Display | MERCK PATENT GMBH (DE) | 2008-05-22 | — | — | US | disclosed |
| US-7361288-B2 | Components for high-frequency technology | MERCK PATENT GESELLSCHAFT MIT BESSCHRANKTER HAFTUNG (DE) | 2008-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080116419-A1 | Mesogenic Compounds, Liquid Crystal Medium and Liquid Crystal Display | CRY1, CRY2, IK | APP 474/4885KCNH2 1169/4885MIF 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.